CD22(low)/Bcl-2(high) expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia

por Wintering, Astrid, Ishiyama, Kenichi, Tamaki, Stanley, Tamaki, Courtney, Fandel, Joshua, Ji, Lingyun, Wood, Brent L., Shah, Nirali N., Yuan, Constance M., O’Brien, Maureen M., Loh, Mignon L., Diaz-Flores, Ernesto
Publicado 2022

Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia

por Pariury, Holly, Fandel, Joshua, Bachl, Stefanie, Ang, Kenny K., Markossian, Sarine, Wilson, Chris G., Braun, Benjamin S., Popescu, Bogdan, Wohlfeil, Margo, Beckman, Kyle, Xirenayi, Simayijiang, Roy, Ritu P., Olshen, Adam B., Smith, Catherine, Arkin, Michelle R., Loh, Mignon L., Diaz-Flores, Ernesto
Publicado 2023